NEW YORK (GenomeWeb) – PerkinElmer said after the close of the market on Thursday that its first quarter revenues were up 5 percent year over year.

The Waltham, Mass.-based company said that for the three months ended March 30, revenues grew to $531.9 million from $505.4 million in the year-ago quarter, edging out the consensus analyst estimate of $531.3 million.

Its Human Health segment posted a 6 percent increase in revenue year over year to $299.5 million from $281.3 million, while its Environmental Health segment grew 4 percent to $232.4 million from $224.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.